Evidence map›Paper›PMID 38650537›Full record

ReviewPediatric transplantation2024

Clinical conundrums in pediatric kidney transplantation: What we know about the role of angiotensin II type I receptor antibodies in pediatric kidney transplantation and the path forward.

Meghan H Pearl

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Meghan H PearlDivision of Pediatric Nephrology, Department of Pediatrics, University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-6070-4793

Funding

Understanding the Interface of Allo and Auto-Immunity: The Impact of Angiotensin II Type 1 Receptor Antibodies in Pediatric Kidney Transplant RecipientsK23AI139335 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PEARL, MEGHAN HALEY · 2019 to 2023
$1.0M
Translational Research Training in Pediatric NephrologyT32DK104687 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALUSKY, ISIDRO B. · 2015 to 2019
$879k
American Society of NephrologyCasey Lee Ball FoundationNational Kidney FoundationNIAID NIH HHS K23 AI139335NIDDK NIH HHS T32 DK104687
6 · The paper itself

Abstract

Antibodies to angiotensin II type 1 receptor (AT1R-Abs) are among the most well-studied non-HLA antibodies in renal transplantation. These antibodies have been shown to be common in pediatric kidney transplantation and associated with antibody-mediated rejection (AMR), vascular inflammation, development of human leukocyte donor-specific antibodies (HLA DSA), and allograft loss. As AT1R-Ab testing becomes more readily accessible, evidence to guide clinical practice for testing and treating AT1R-Ab positivity in pediatric kidney transplant recipients remains limited. This review discusses the clinical complexities of evaluating AT1R-Abs given the current available evidence.

Indexed as

Graft RejectionKidney TransplantationReceptor, Angiotensin, Type 1AutoantibodiesChildHLA AntigensHumansIsoantibodiesAutoantibodiesHLA AntigensIsoantibodiesReceptor, Angiotensin, Type 1angiotensin II type 1 receptor antibodycytokineendothelin type A receptor antibodyhuman leukocyte antigen donor‐specific antibodypediatric nephrologytransplantation

Identifiers

PMID38650537
PMCPMC11060698

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.